#nirmatrelvir — Public Fediverse posts

Oral #Nirmatrelvir – Ritonavir for #Covid19 in Higher-Risk #Outpatients, https://etidiohnew.blogspot.com/2026/04/oral-nirmatrelvir-ritonavir-for-covid19.html

Effectiveness of #nirmatrelvir/ritonavir and #molnupiravir in reducing the #risk of short-term and long-term #cardiovascular complications of #COVID19: a target trial emulation study, https://etidiohnew.blogspot.com/2025/12/effectiveness-of-nirmatrelvirritonavir.html

#Antiviral efficacy of oral #ensitrelvir versus oral ritonavir-boosted #nirmatrelvir in #COVID19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial, https://etidiohnew.blogspot.com/2025/10/antiviral-efficacy-of-oral-ensitrelvir.html

#Placental transfer of #medications to treat #COVID19, #molnupiravir, #favipiravir and #nirmatrelvir/ritonavir, in the ex vivo human cotyledon model, https://etidiohnew.blogspot.com/2025/09/placental-transfer-of-medications-to.html

Extended #nirmatrelvir–ritonavir #treatment durations for immunocompromised #patients with #COVID19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial, https://etidiohnew.blogspot.com/2025/07/extended-nirmatrelvirritonavir.html

Well… #Dinner last night. Neither of us ate.

I woke not long ago with a stomach ache though. A good burp seems to have fixed that.

The last of my #Paxlovid #nirmatrelvir #ritonavir has been taken.

My Dr is now on holiday, so I guess I just wait & see what happens with my #Covid.

Still have a few days of #BellsPalsy meds left. My lips have been very active the last few days, doing their #MexicanWave at random times.

More rain inbound. I’ll feed the #alpacas & #sheep before it arrives.

#Molnupiravir or #nirmatrelvir–ritonavir plus usual care vs usual care alone in patients admitted to #hospital with #COVID19 (RECOVERY)..., https://etidiohnew.blogspot.com/2025/05/molnupiravir-or-nirmatrelvirritonavir.html

#Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with #longCOVID in the #USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial, https://etidiohnew.blogspot.com/2025/04/nirmatrelvirritonavir-versus.html

Modeling suggests #SARS-CoV-2 #rebound after #nirmatrelvir-ritonavir #treatment is driven by target cell preservation coupled with incomplete viral clearance, https://etidiohnew.blogspot.com/2025/02/modeling-suggests-sars-cov-2-rebound.html

Distal #protein-protein #interactions contribute to #nirmatrelvir #resistance, https://etidiohnew.blogspot.com/2025/02/distal-protein-protein-interactions.html

#Structural and #virologic #mechanism of the emergence of #resistance to #Mpro #inhibitors in #SARS-CoV-2, PNAS: https://www.pnas.org/doi/abs/10.1073/pnas.2404175121?af=R

We generated SARS-CoV-2 variants resistant to three SARS-CoV-2 main protease (Mpro) inhibitors (#nirmatrelvir, TKB245, and 5h), by propagating the ancestral SARS-CoV-2WK521WT in VeroE6TMPRSS2 cells with increasing concentrations of each inhibitor and examined their structural and virologic profiles.

Oral #Nirmatrelvir–Ritonavir as #Postexposure #Prophylaxis for #Covid19, N Engl J Med.: https://www.nejm.org/doi/full/10.1056/NEJMoa2309002

In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir–ritonavir for 5 or 10 days did not significantly reduce the #risk of symptomatic #SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, NCT05047601.)

Oral #Nirmatrelvir–Ritonavir as #Postexposure #Prophylaxis for #Covid19, N Engl J Med.: https://www.nejm.org/doi/full/10.1056/NEJMoa2309002

In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir–ritonavir for 5 or 10 days did not significantly reduce the #risk of symptomatic #SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, NCT05047601.)

Oral #Nirmatrelvir–Ritonavir as #Postexposure #Prophylaxis for #Covid19, N Engl J Med.: https://www.nejm.org/doi/full/10.1056/NEJMoa2309002

In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir–ritonavir for 5 or 10 days did not significantly reduce the #risk of symptomatic #SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, NCT05047601.)

Oral #Nirmatrelvir–Ritonavir as #Postexposure #Prophylaxis for #Covid19, N Engl J Med.: https://www.nejm.org/doi/full/10.1056/NEJMoa2309002

In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir–ritonavir for 5 or 10 days did not significantly reduce the #risk of symptomatic #SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, NCT05047601.)

Oral #Nirmatrelvir–Ritonavir as #Postexposure #Prophylaxis for #Covid19, N Engl J Med.: https://www.nejm.org/doi/full/10.1056/NEJMoa2309002

In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir–ritonavir for 5 or 10 days did not significantly reduce the #risk of symptomatic #SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, NCT05047601.)

Comparative #effectiveness of #combination #therapy with #nirmatrelvir–ritonavir & #remdesivir versus #monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with #COVID19: a target #trial emulation study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00353-0/fulltext?rss=yes

Our study highlighted the potential for reduced #risk of #mortality, #ICU admission, or need for ventilatory support in patients hospitalised with COVID-19 treated with nirmatrelvir–ritonavir as a monotherapy ...

Comparative #effectiveness of #combination #therapy with #nirmatrelvir–ritonavir & #remdesivir versus #monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with #COVID19: a target #trial emulation study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00353-0/fulltext?rss=yes

Our study highlighted the potential for reduced #risk of #mortality, #ICU admission, or need for ventilatory support in patients hospitalised with COVID-19 treated with nirmatrelvir–ritonavir as a monotherapy ...

Comparative #effectiveness of #combination #therapy with #nirmatrelvir–ritonavir & #remdesivir versus #monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with #COVID19: a target #trial emulation study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00353-0/fulltext?rss=yes

Our study highlighted the potential for reduced #risk of #mortality, #ICU admission, or need for ventilatory support in patients hospitalised with COVID-19 treated with nirmatrelvir–ritonavir as a monotherapy ...

Comparative #effectiveness of #combination #therapy with #nirmatrelvir–ritonavir & #remdesivir versus #monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with #COVID19: a target #trial emulation study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00353-0/fulltext?rss=yes

Our study highlighted the potential for reduced #risk of #mortality, #ICU admission, or need for ventilatory support in patients hospitalised with COVID-19 treated with nirmatrelvir–ritonavir as a monotherapy ...

Comparative #effectiveness of #combination #therapy with #nirmatrelvir–ritonavir & #remdesivir versus #monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with #COVID19: a target #trial emulation study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00353-0/fulltext?rss=yes

Our study highlighted the potential for reduced #risk of #mortality, #ICU admission, or need for ventilatory support in patients hospitalised with COVID-19 treated with nirmatrelvir–ritonavir as a monotherapy ...

A unifying #model to explain frequent #SARS-CoV-2 #rebound after #nirmatrelvir #treatment and limited prophylactic #efficacy https://www.nature.com/articles/s41467-024-49458-9

Here authors develop a mathematical model for viral-immune dynamics & nirmatrelvir #pharmacokinetics and suggest that early treatment preserves susceptible cells & blunts innate immune response without fully eliminating infection. They project that treatment extension for 10 days may overcome this effect.

A unifying #model to explain frequent #SARS-CoV-2 #rebound after #nirmatrelvir #treatment and limited prophylactic #efficacy https://www.nature.com/articles/s41467-024-49458-9

Here authors develop a mathematical model for viral-immune dynamics & nirmatrelvir #pharmacokinetics and suggest that early treatment preserves susceptible cells & blunts innate immune response without fully eliminating infection. They project that treatment extension for 10 days may overcome this effect.

A unifying #model to explain frequent #SARS-CoV-2 #rebound after #nirmatrelvir #treatment and limited prophylactic #efficacy https://www.nature.com/articles/s41467-024-49458-9

Here authors develop a mathematical model for viral-immune dynamics & nirmatrelvir #pharmacokinetics and suggest that early treatment preserves susceptible cells & blunts innate immune response without fully eliminating infection. They project that treatment extension for 10 days may overcome this effect.

A unifying #model to explain frequent #SARS-CoV-2 #rebound after #nirmatrelvir #treatment and limited prophylactic #efficacy https://www.nature.com/articles/s41467-024-49458-9

Here authors develop a mathematical model for viral-immune dynamics & nirmatrelvir #pharmacokinetics and suggest that early treatment preserves susceptible cells & blunts innate immune response without fully eliminating infection. They project that treatment extension for 10 days may overcome this effect.

A unifying #model to explain frequent #SARS-CoV-2 #rebound after #nirmatrelvir #treatment and limited prophylactic #efficacy https://www.nature.com/articles/s41467-024-49458-9

Here authors develop a mathematical model for viral-immune dynamics & nirmatrelvir #pharmacokinetics and suggest that early treatment preserves susceptible cells & blunts innate immune response without fully eliminating infection. They project that treatment extension for 10 days may overcome this effect.

#Nirmatrelvir #Resistance in an Immunocompromised #Patient with Persistent #COVI19, Viruses: https://www.mdpi.com/1999-4915/16/5/718

The impact of drug-resistant SARS-CoV-2 on the #clinical course, including its #severity, remains unknown. Our study is important for examining the clinical impact of nirmatrelvir resistance in COVID-19.

"#Paxlovid ® ab sofort in der regulären Handelskette

Bislang wurde die Versorgung mit der antiviralen Wirkstoffkombi #Nirmatrelvir/#Ritonavir aus Beständen bedient, die vom Bund beschafft wurden. Das ändert sich jetzt."

#Corona #Coronavirus #COVID19 #LongCovid #PostCovid #MECFS #POTS

https://www.aerztezeitung.de/Wirtschaft/Paxlovid-ab-sofort-in-der-regulaeren-Handelskette-446246.html

Harrington PR, Cong J, Troy SB, et al. #Evaluation of #SARS-CoV-2 #RNA #Rebound After #Nirmatrelvir/Ritonavir #Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — #USA and International Sites, 2021–2022. MMWR Morb Mortal Wkly Rep 2023;72:1365–1370. DOI: http://dx.doi.org/10.15585/mmwr.mm7251a2

Optimal #timing of #nirmatrelvir/ritonavir #treatment after #COVID19 symptom #onset or #diagnosis: target trial emulation https://www.nature.com/articles/s41467-023-43706-0

Studie über "SARS-CoV-2 Virologic Rebound unter Nirmatrelvir–Ritonavir-Therapie" https://www.dmz-news.eu/2023/12/01/studie-%C3%BCber-sars-cov-2-virologic-rebound-unter-nirmatrelvir-ritonavir-therapie/ #COVID19 #Coronavirus #BildungAberSicherCH #ProtectTheKids #Covid #SARSCoV2 #Covid19 #Covid_19 #LongCovid #Pandemie #Ritonavir #Nirmatrelvir #Rebound

Effectiveness of #Nirmatrelvir–#Ritonavir #Paxlovid Against the Development of #PostCOVID 19 Conditions Among U.S. Veterans

https://t.ly/b1gfK

“Out of 31 potential #PCCs, only combined thromboembolic events seemed to be reduced by nirmatrelvir–ritonavir”

One of the authors does a 5-minute video at the link

@longcovid
#LongCovid #PwLC #PostCovidSyndrome #LC #PASC @covid19
#COVIDー19 #COVID19 #COVID #COVID_19 #SARSCoV2 @novid #novid #CovidIsNotOver #CovidBrain

''WHO continues to strongly recommend #nirmatrelvir-ritonavir (also known by its brand name ‘#Paxlovid’) for people at high-risk and moderate #risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022''

A retrospective cohort study of prescribing #outcomes in #outpatients treated with #nirmatrelvir–Ritonavir for #COVID19 in an interdisciplinary community clinic https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0293302

Evidence that oral antivirals have a beneficial impact on #COVID19 in high-risk patients. #nirmatrelvir #molnupiravir #Paxlovid

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804227

"I’m glad to see this paper - it’s a look from Pfizer about how they were able to scale up #nirmatrelvir (the antiviral component of the #Paxlovid combination) so quickly. The authors are surely correct when they say that this 17-month timeline is a record for the drug industry, and it’s very much worth seeing how this all happened."
#Antiviral #drugdevelopment #covid19

https://www.science.org/content/blog-post/paxlovid-drug-development-full-sprint

[Articles] #Effectiveness of #nirmatrelvir–ritonavir in preventing #hospital #admissions and #deaths in people with #COVID19: a cohort study in a large #US health-care system https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00118-4/fulltext?rss=yes

[Comment] Real-world #effectiveness of #nirmatrelvir–ritonavir against #BA4 and #BA5 #omicron #SARS-CoV-2 #variants https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00056-7/fulltext?rss=yes

[Articles] Real-world use of #nirmatrelvir–ritonavir in #outpatients with #COVID19 during the era of #omicron #variants including #BA4 and #BA5 in #Colorado, #USA: a retrospective cohort study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00011-7/fulltext?rss=yes

子陵在听歌
2023-01-09 https://weibo.com/1251560221/MnseR2Rx3

#新型冠状病毒 SARS-CoV-2是一个正链#RNA病毒，不是#逆转录病毒，它没有#逆转录酶。#阿兹夫定 是一个活性不强的#HIV 逆转录酶#抑制剂，对SARS-CoV-2没有#抗病毒活性。而#Paxlovid 中的有效成分#Nirmatrelvir 是用最先进的#药化设计 方法根据SARS-CoV-2蛋白酶Mpro（3CL）#构象结构 修饰出来的（https://weibo.com/1251560221/LbrLu7UAZ ）。

阿兹夫定没有任何发表在#同行审阅 杂志上的有效性#临床试验 结果（https://weibo.com/7597822550/Mn9EBCRlo ）。Paxlovid的有效性#3期临床试验 结果发表在全世界最权威的医学杂志#NEJM 上，是目前唯一能降低SARS-CoV-2#病毒载量 的#小分子抗病毒药（https://weibo.com/1251560221/M4Ut7y5TQ ）；在其上市后多个独立的第三方机构在权威#医学杂志 上发表了其真实世界有效性数据。

其实每个国家都有相关政策保护自己的#民族工业，对我而言，这并不陌生。如果去翻我之前的微博，我在微博上追踪了#抗病毒药 十几年，见证了很多重磅抗病毒药在#CDE 和#医保局 来来回回洽谈多年，比如#DTG 和#必妥维。HIV药物可以用几年来谈，但是在#重大传染病 #公共卫生 危机中，还用惯性方法去处理危机，可见一些机构的优先级是什么。当然，没有医学#科学训练、也非#医药卫生行业 从业者的人可能为此叫好，但接受过相关训练的从业者则无话可说。

———— ⁂ ————

分析#阿兹夫定 的#临床试验数据：一个打死不冤的伪#新冠特效药

Y博的科普园 一个生物狗的科普小园 2023-01-07 https://mp.weixin.qq.com/s/IrIfACWflj6ZwGe6CqHERw

申明：仅代表个人观点，不代表任何组织与单位

这几天有报道说阿兹夫定的#三期临床试验 公布，显著缩短核酸转阴时间。这个药之前写过很多，#有效性极为可疑，安全性上的#遗传、#生殖毒性 问题更无法解决（详见二条）。
但很多人还在问，所以就去看了所谓显示有效的#巴西 三期临床试验，其实根本谈不上显示有效性，部分内容也与之前相关药企IPO文件里提到的其它#临床试验 结果冲突。此药能上架就已荒唐，如果你有（不）幸拿到阿兹夫定，扔了算了。